Table 2.
Efficacy of clinical and preclinical compounds against SARS-CoV-2 in cell cultures.
| Compound | Original indication | Clinical status | EC50 [μM] | TC50 [μM] | Susceptible cell lines (n.) |
|---|---|---|---|---|---|
| A0001 | Friedreich ataxia | Phase II | 0.497 | 8.4 | 0 |
| Methylene Blue | Methemoglobinemia | Launched | 1.426 | 8.709 | 2 |
| MLN4924 | Cancer | Phase II | 0.032 | 40.39 | 3 |
| Mycophenolic acid | Immunosuppressant | Launched | 1.85 | 45.823 | 3 |
| OTSSP167 | Cancer | Experimental | 0.041 | 0.766 | 0 |
| Posaconazole | Antifungal | Launched | 4.2 | >50 | 3 |
| R788-Fostamatinib | Immune thrombo-cytopenic purpura | Launched | 1.331 | 14.709 | 2 |
| Ro 48-8071 | Cancer | Experimental | 1.859 | 8.642 | 4 |
Repurposing compounds at different stages of clinical development with good separation of hCoV-229E-GFP inhibition and toxicity (columns 4 and 5) were selected, and tested for anti-viral efficacy against SARS-CoV-2 in nasal and bronchial HAEEC. Effects against SARS-CoV-2 in four different cell lines (Vero E6, Huh7-ACE2, A549-ACE2, and Hela-ACE2) are indicated in the last column.